Estados financieros detallados de Inotiv, Inc. (NOTV): cuenta de resultados, balance general y flujo de caja. Sigue la evolución de márgenes, deuda, liquidez y rentabilidad año a año con hasta 20 años de histórico.
Resumen del Análisis
Inotiv, Inc. registró ingresos de $513.0M en el último ejercicio fiscal, con un CAGR de 5 años del 53.4%.
Márgenes de los últimos 12 meses: margen bruto 14.7%, margen operativo -8.9%, margen neto -17.1%.
Al precio actual de $0.08, NOTV presenta beneficios negativos (P/E no significativo) y un ROE del -74.67%. La capitalización bursátil es de $3M.
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | $20.4M | $24.2M | $26.3M | $43.6M | $60.5M | $89.6M | $547.7M | $572.4M | $490.7M | $513.0M |
| Coste de Ventas | $16.0M | $16.5M | $18.2M | $30.7M | $42.2M | $59.4M | $390.4M | $407.0M | $379.6M | $448.0M |
| Beneficio Bruto | $4.4M | $7.7M | $8.1M | $12.9M | $18.2M | $30.2M | $157.2M | $165.4M | $111.2M | $65.1M |
| I+D | $496000 | $465000 | $596000 | $627000 | $950000 | $405000 | 0 | 0 | 0 | 0 |
| Generales y Administrativos | $6.0M | $6.0M | $7.5M | $12.4M | $20.4M | $33.9M | $99.1M | $127.3M | $97.9M | $92.2M |
| Gastos Operativos | $6.5M | $6.4M | $8.1M | $13.1M | $21.3M | $35.8M | $184.7M | $246.9M | $197.6M | $96.0M |
| Beneficio Operativo | -$3.0M | $1.3M | $14000 | -$153000 | -$3.1M | $1.5M | -$27.4M | -$81.5M | -$86.4M | -$30.9M |
| EBITDA | -$1.3M | $3.0M | $1.9M | $2.6M | $1.0M | $15.4M | -$273.4M | -$26.5M | -$26.8M | $24.8M |
| Gastos por Intereses | $399000 | $375000 | $274000 | $642000 | $1.5M | $1.7M | $29.7M | $43.0M | $46.9M | $56.6M |
| Beneficio Antes de Impuestos | -$3.2M | $908000 | -$254000 | -$786000 | -$4.5M | $6.1M | -$352.4M | -$124.2M | -$130.8M | -$87.8M |
| Impuestos | -$14000 | $24000 | -$60000 | $4000 | $147000 | -$4.8M | -$15.2M | -$19.3M | -$21.9M | -$19.1M |
| Beneficio Neto | -$3.2M | $884000 | -$194000 | -$790000 | -$4.7M | $10.9M | -$337.3M | -$105.1M | -$108.4M | -$68.6M |
| BPA | $-0.40 | $0.11 | $-0.02 | $-0.08 | $-0.43 | $0.83 | $-13.85 | $-4.10 | $-4.19 | $-2.11 |
| BPA Diluido | $-0.40 | $0.10 | $-0.02 | $-0.08 | $-0.43 | $0.79 | $-13.85 | $-4.10 | $-4.19 | $-2.11 |
| Acciones en Circulación (Diluidas) | $8.1M | $8.7M | $8.8M | $10.4M | $10.9M | $13.9M | $24.4M | $25.6M | $25.9M | $32.5M |
Balance (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Caja y Equivalentes | $386000 | $434000 | $773000 | $606000 | $1.4M | $138.9M | $18.5M | $35.5M | $21.4M | $21.7M |
| Inversiones a Corto | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cuentas por Cobrar | $2.2M | $3.1M | $5.1M | $9.5M | $10.8M | $28.4M | $100.1M | $90.4M | $77.4M | $97.4M |
| Inventario | $1.5M | $913000 | $1.2M | $1.1M | $700000 | $602000 | $71.4M | $56.1M | $18.2M | $45.7M |
| Activos Corrientes | $4.9M | $5.3M | $8.1M | $12.4M | $15.3M | $189.0M | $233.0M | $213.8M | $163.4M | $194.6M |
| Inmovilizado Material | $16.1M | $15.0M | $16.6M | $22.8M | $37.5M | $56.4M | $218.7M | $229.9M | $237.5M | $227.1M |
| Fondo de Comercio | $38000 | $38000 | $3.1M | $3.6M | $4.4M | $51.9M | $157.8M | $94.3M | $94.3M | $94.3M |
| Activos Intangibles | 0 | 0 | $3.3M | $2.9M | $4.3M | $24.2M | $345.9M | $308.4M | $274.4M | $240.2M |
| Activos Totales | $21.1M | $20.4M | $31.3M | $42.0M | $61.6M | $321.9M | $962.9M | $856.5M | $781.4M | $771.1M |
| Cuentas por Pagar | $3.0M | $2.1M | $3.2M | $4.9M | $3.2M | $6.2M | $28.7M | $32.6M | $33.5M | $48.5M |
| Deuda a Corto | $5.0M | $352000 | $996000 | $2.2M | $6.9M | $11.4M | $23.0M | $8.0M | $3.5M | $405.1M |
| Pasivos Corrientes | $13.5M | $7.7M | $11.8M | $17.5M | $31.6M | $55.1M | $164.1M | $132.2M | $119.0M | $556.8M |
| Deuda a Largo | 0 | $4.2M | $8.5M | $13.8M | $18.8M | $154.2M | $330.7M | $369.8M | $389.8M | $44.3M |
| Pasivos Totales | $13.7M | $11.9M | $20.4M | $31.3M | $54.0M | $216.7M | $603.1M | $588.0M | $610.9M | $635.1M |
| Reservas | -$16.9M | -$16.0M | -$16.2M | -$17.1M | -$21.9M | -$11.0M | -$348.3M | -$453.3M | -$562.2M | -$630.8M |
| Patrimonio Neto | $7.5M | $8.5M | $10.9M | $10.7M | $7.6M | $105.1M | $360.4M | $269.2M | $170.5M | $136.0M |
| Deuda Total | $5.3M | $4.7M | $9.7M | $16.6M | $36.4M | $174.2M | $386.5M | $417.6M | $445.1M | $503.6M |
| Deuda Neta | $5.0M | $4.3M | $8.9M | $16.0M | $35.0M | $35.3M | $368.0M | $382.1M | $423.7M | $481.9M |
| Capital Circulante | -$8.6M | -$2.4M | -$3.7M | -$5.1M | -$16.3M | $133.9M | $68.9M | $81.6M | $44.4M | -$362.2M |
Flujo de Caja (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Beneficio Neto | -$3.2M | $884000 | -$194000 | -$790000 | -$4.7M | $10.9M | -$337.3M | -$104.9M | -$108.9M | -$68.6M |
| Amortizaciones | $1.6M | $1.7M | $1.9M | $2.7M | $3.9M | $6.3M | $49.3M | $54.7M | $57.1M | $55.9M |
| Compensación en Acciones | $45000 | $19000 | $134000 | $278000 | $540000 | $1.8M | $24.2M | $7.8M | $6.7M | $6.0M |
| Cambio en Capital Circulante | $1.8M | -$1.3M | $1.7M | -$92000 | $948000 | $9.6M | -$40.3M | $17.0M | $52.6M | -$1.1M |
| Flujo de Caja Operativo | $1.1M | $1.2M | $3.5M | $1.8M | $1.3M | $10.7M | -$5.2M | $27.9M | -$6.8M | -$10.5M |
| Inversiones (CapEx) | -$1.3M | -$347000 | -$1.3M | -$6.9M | -$6.2M | -$12.5M | -$36.3M | -$27.5M | -$22.3M | -$16.6M |
| Adquisiciones | 0 | $8000 | -$6.8M | -$1.3M | -$3.9M | -$41.6M | -$297.7M | $1.1M | 0 | 0 |
| Recompra de Acciones | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividendos Pagados | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Flujo de Caja Libre | -$196000 | $889000 | $2.2M | -$5.1M | -$4.9M | -$1.7M | -$41.5M | $380000 | -$29.1M | -$27.1M |
Crecimiento y Márgenes (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Crecimiento Ingresos (anual) | +18.6% | +8.7% | +65.6% | +38.6% | +48.2% | +511.2% | +4.5% | -14.3% | +4.5% | |
| Crecimiento Beneficio Neto (anual) | +127.4% | -121.9% | -307.2% | -493.0% | +332.6% | -3195.6% | +68.8% | -3.1% | +36.7% | |
| Crecimiento BPA (anual) | +127.5% | -120.1% | -244.3% | -465.0% | +293.0% | -1768.7% | +70.4% | -2.2% | +49.6% | |
| Cambio en Acciones (anual) | +7.7% | +0.4% | +18.4% | +4.5% | +27.8% | +75.7% | +5.3% | +1.0% | +25.3% | |
| Crecimiento FCF (anual) | +553.6% | +144.1% | -335.1% | +3.7% | +64.8% | -2305.4% | +100.9% | -7761.8% | +7.0% | |
| Margen Bruto | 21.6% | 31.8% | 30.8% | 29.6% | 30.2% | 33.7% | 28.7% | 28.9% | 22.7% | 12.7% |
| Margen Operativo | -14.9% | 5.3% | 0.1% | -0.4% | -5.1% | 1.7% | -5.0% | -14.2% | -17.6% | -6.0% |
| Margen EBITDA | -6.3% | 12.2% | 7.1% | 5.9% | 1.7% | 17.1% | -49.9% | -4.6% | -5.5% | 4.8% |
| Margen Neto | -15.8% | 3.6% | -0.7% | -1.8% | -7.7% | 12.2% | -61.6% | -18.4% | -22.1% | -13.4% |
| Margen FCF | -1.0% | 3.7% | 8.2% | -11.7% | -8.1% | -1.9% | -7.6% | 0.1% | -5.9% | -5.3% |
| Tasa Impositiva Efectiva | 0.4% | 2.6% | 23.6% | -0.5% | -3.2% | -78.1% | 4.3% | 15.6% | 16.7% | 21.8% |
Datos por Acción (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| FCF por Acción | $-0.02 | $0.10 | $0.25 | $-0.49 | $-0.45 | $-0.12 | $-1.70 | $0.01 | $-1.12 | $-0.83 |
| Dividendo por Acción | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Acciones en Circulación (Básicas) | $8.1M | $8.2M | $8.8M | $10.4M | $10.9M | $13.2M | $24.4M | $25.6M | $25.9M | $32.5M |
Qué mirar en Salud / Farma
El pipeline de I+D es el activo invisible. Patentes que caducan = ingresos que evaporan. Mira innovación y flujo de caja.
- I+D / Ingresos — Indica inversión en pipeline futuro. Farma seria reinvierte 15-20%
- Crecimiento EPS 5y — Tras caducidad de patentes, ¿siguen creciendo?
- Margen bruto — Farma de marca >70%. Genéricos mucho más bajo — define el tipo de negocio
- FCF / Net Income — Calidad del beneficio — farma grande debería convertir >90%
- ROIC — Capital reinvertido con eficiencia — clave en farma por ciclos de I+D largos
- Deuda neta / EBITDA — Adquisiciones de farma generan mucha deuda — ojo al post-M&A
- P/E vs historial 10y propio — La mejor comparación es con su propia historia, no con competidores
Rentabilidad
| Rentabilidad sobre capital | -74.67% |
| Rentabilidad sobre capital invertido | -6.25% |
| Rentabilidad sobre activos | -12.38% |
| Margen bruto | 14.70% |
| Margen operativo | -8.87% |
| Margen neto | -17.14% |
Salud financiera
| Deuda / Patrimonio | 6.33 |
| Ratio corriente | 0.27 |
Ratios Clave (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E | -2.87 | 16.00 | -75.11 | -47.17 | -11.12 | 35.23 | -1.22 | -0.75 | -0.41 | -0.69 |
| P/VC | 1.25 | 1.70 | 1.34 | 3.48 | 6.83 | 3.67 | 1.14 | 0.29 | 0.26 | 0.35 |
| P/V | 0.46 | 0.59 | 0.55 | 0.85 | 0.86 | 4.30 | 0.75 | 0.14 | 0.09 | 0.09 |
| Margen Bruto | 21.6% | 31.8% | 30.8% | 29.6% | 30.2% | 33.7% | 28.7% | 28.9% | 22.7% | 12.7% |
| Margen Operativo | -14.9% | 5.3% | 0.1% | -0.4% | -5.1% | 1.7% | -5.0% | -14.2% | -17.6% | -6.0% |
| Margen Neto | -15.8% | 3.6% | -0.7% | -1.8% | -7.7% | 12.2% | -61.6% | -18.4% | -22.1% | -13.4% |
Empresas relacionadas: BDSX · BEAT · BIAF · CELU · FGEN · KZR · QNTM
Explorar sector: Healthcare · Medical - Diagnostics & Research
Más secciones de NOTV: Resumen · Valoración · Estadísticas · Estimaciones · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones